Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline Phase 2 in IBS-D
NCT01130272Phase 2Completed
- Sponsor
- Furiex Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eluxadoline in Irritable bowel syndrome with diarrhea (IBS-D) (5 arms), sponsored by Furiex Pharmaceuticals. Primary endpoint: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
eluxadoline
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT01130272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130272.